Table 2.
Treatments and outcomes of patients with moderate coronavirus disease 2019
| Total (n = 456) | No progression (n = 205) | Poor prognoses (n = 251) | p value | |
|---|---|---|---|---|
| Treatment | ||||
| Antivirala | 437 (95.83%) | 193 (94.14%) | 244 (97.21%) | 0.103 |
| Antibioticb | 369 (80.92%) | 173 (84.39%) | 196 (78.08%) | 0.088 |
| Glucocorticoids | 226 (49.56%) | 70 (34.14%) | 156 (62.15%) | <0.001 |
| Intravenous immunoglobulin | 145 (31.79%) | 54 (26.31%) | 91 (36.25%) | 0.024 |
| Outcomes | ||||
| Time from illness onset to admission, days | 7 (4.25–14) | 8 (4–14) | 7 (5–11) | 0.135 |
| Severe progression | — | — | 155 (61.75%) | |
| Critical progression | — | — | 50 (19.92%) | |
| Death progression | — | — | 46 (18.33%) | |
Data are n (%). Normal distributed data are mean ± SD and non-normal distributed data are median (IQR).
a
Antiviral treatments included ribavirin, arbidol and lopinavir/ritonavir.
b
Antibiotic treatments included cephalosporins and quinolones.